Navigation Links
Verenium Advances Its Development Work With Cargill on a New Food-Related Product
Date:9/13/2007

CAMBRIDGE, Mass., Sept. 13 /PRNewswire-FirstCall/ -- Verenium Corporation (Nasdaq: VRNM), a leading developer of technologies for cellulosic ethanol production and a pioneer in the development of high-performance specialty enzymes, announced today that it has achieved a key technical milestone in its collaboration with Cargill on a new food-related product designed to promote healthy lifestyle choices for global consumers.

Under the agreement between Verenium and Cargill, Verenium is applying its enzyme discovery and optimization technologies to develop several new custom enzymes for Cargill, which are being utilized as part of Cargill's innovative, multi-step enzymatic process to develop a new food-related product.

Verenium is eligible to receive future milestone payments, licensing fees, and product royalties as a result of this joint research and development work with Cargill. Verenium has received research funding in addition to payments from Cargill for meeting previous technical milestones.

"We are very pleased that our collaboration with Verenium continues to produce excellent results ahead of schedule," said Chris Mallett, Corporate Vice President, Research and Development, Cargill. "We look forward to further technical success from our collaboration as we move towards the commercialization of this important new consumer product," he added.

"We are enthusiastic with the continued progress of this collaboration and are especially pleased that our custom enzymes are enabling Cargill to develop this innovative consumer product," said Carlos A. Riva, President and Chief Executive Officer, Verenium. "Success in this technically demanding project highlights the potential of Verenium's enzyme discovery and development platforms to provide unique solutions to unmet market needs."

About Verenium

Verenium Corporation is a leader in the development and commercialization of cellulosic ethanol, an environmentally-friendly and renewable transportation fuel, as well as high-performance specialty enzymes for applications within the biofuels, industrial, and health and nutrition markets. The Company possesses integrated, end-to-end capabilities in pre-treatment, novel enzyme development, fermentation, engineering, and project development and is moving rapidly to commercialize its proprietary technology for the production of ethanol from a wide array of feedstocks, including sugarcane bagasse, dedicated energy crops, agricultural waste, and wood products. In addition to the vast potential for biofuels, a multitude of large-scale industrial opportunities exist for the Company for products derived from the production of low-cost, biomass-derived sugars.

Verenium's Specialty Enzyme business harnesses the power of enzymes to create a broad range of specialty products to meet high-value commercial needs. Verenium's world class R&D organization is renowned for its capabilities in the rapid screening, identification, and expression of enzymes-proteins that act as the catalysts of biochemical reactions.

Verenium recently completed a significant upgrade of one of the nation's first operational cellulosic ethanol pilot facilities located in Jennings, Louisiana and expects to achieve mechanical completion of a 1.4 million gallon-per-year, demonstration-scale facility to produce cellulosic ethanol by the first quarter of 2008. In addition, the Company's process technology has been licensed by Tokyo-based Marubeni Corp. and Tsukishima Kikai Co., LTD and has been incorporated into BioEthanol Japan's 1.4 million liter-per-year cellulosic ethanol plant in Osaka, Japan -- the world's first commercial-scale plant to produce cellulosic ethanol from wood construction waste. For more information on Verenium, visit http://www.verenium.com.

About Cargill

Cargill is an international provider of food, agricultural and risk management products and services. With 158,000 employees in 66 countries, the company is committed to using its knowledge and experience to collaborate with customers to help them succeed. For more information, visit http:www.cargill.com.

Forward Looking Statements

Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty. These include statements related to the development of novel enzymes under the agreement with Cargill, Verenium's ability to achieve milestones under the agreement, potential new future collaborations between Verenium and Cargill, and potential solutions that may be discovered from Verenium's enzyme libraries, all of which are prospective. Such statements are only predictions, and the actual events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to differences include, but are not limited to, risks involved in general with the enzyme development process, risks involved with Verenium's new and uncertain technologies, Verenium's dependence on patents and proprietary rights, Verenium's protection and enforcement of its patents and proprietary rights, the timing and composition of funding under existing and future collaboration agreements, Verenium's dependence on Cargill in connection with this agreement, Cargill's ability to further develop any enzymes developed under this agreement (if Cargill exercises its option to do so), Verenium's and Cargill's ability to commercialize products, the time and resources needed to develop new products and obtain any necessary regulatory approvals, customer adoption of new products, the development or availability of competitive products or technologies, Certain of these factors and others are more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's Quarterly Report on Form 10-Q for the quarter ended June 30, 2007. These forward-looking statements speak only as of the date hereof. Verenium expressly disclaims any intent or obligation to update these forward-looking statements.

Contacts:

Verenium Corporation

Kelly Lindenboom

Vice President, Corporate Communications

617-674-5335

kelly.lindenboom@verenium.com


'/>"/>
SOURCE Verenium Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. The Affymetrix GeneChip Scanner 3000 New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range
2. Quintessence Biosciences advances cancer drug
3. Healthcare slow to adopt genetic advances
4. Wireless advances in Madison, heats up in Waukesha
5. GE Healthcares CT Scanner advances coronary imaging
6. Cancer treatment advances as trials show no harm to mice
7. New CT scanner by GE Healthcare advances imaging technology
8. Small wonders: Intersection of biotech and nanotech will produce big advances
9. Standards Needed for Advances in Healthcare Technology
10. The let-7 microRNA Family Regulates RAS: Implications for Development and Oncogenesis
11. Rapid Method Development With the BioLogic DuoFlow Chromatography System for the Purification of His-Tagged Proteins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... HOUSTON , June 23, 2016 ... agreement with the Cy-Fair Sports Association to serve ... of the agreement, Houston Methodist Willowbrook will provide ... education and connectivity with association coaches, volunteers, athletes ... partner with the Cy-Fair Sports Association and to ...
(Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest features ... will also be presenting a scientific poster on Disrupting Clinical Trials in The ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
Breaking Biology News(10 mins):